Guardant Health Inc. (GH)
NASDAQ: GHHealth CareMedical SpecialitiesUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
GH stock chart
Technical analysisKey statistics
All statistics- Market cap
- $19.73B
- EPS (TTM)
- -$3.68
- Dividend yield
- None
- 52-week range
- 74.55 – 191.05
- Day range
- 141.01 – 148.26
- Volume / Avg
- 2.76M / 1.97M
- Beta
- —
- Shares outstanding
- 135.29M
52-week range
GH stock today
Shares of Guardant Health (GH) finished higher on Nov 20 at $145.83, a gain of 0.16% or $0.24 per share, versus the S&P 500's 3.70% decline. Shares are 23.7% below their 52-week high of $191.05, set on Oct 6, 2026 and 95.6% above the 52-week low of $74.55, in the middle of the past year's range. GH is up 42.8% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 38.3%.
Guardant Health has posted a net loss over the last twelve months (EPS of -$3.68), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Guardant Health
Company profileGuardant Health, Inc., a precision oncology company, provides blood and tissue tests, and data sets in the United States and internationally. The company offers Guardant360 CDx test, a liquid biopsy test for tumor mutation profiling; Guardant360 Liquid test, which measures 740+ genes and supports all guideline-recommended biomarkers; Guardant Reveal test, a blood test that utilizes circulating tumor DNA to detect cancer at the molecular level; and Guardant360 Tissue test, a molecular profiling test for tumor tissue that provides genomic, transcriptomic, and epigenomic insights. It also provides Shield blood test for colorectal cancer screening in adults.
- Sector
- Health Care
- Industry
- Medical Specialities
- CEO
- Dr. Helmy Eltoukhy Ph.D.
- Headquarters
- Palo Alto, CA
- Employees
- 2,490
- IPO year
- 2018
- Website
- guardanthealth.com
Financial highlights
Full financialsIn fiscal 2025, Guardant Health generated $982.0 million in revenue, up 32.9% from fiscal 2024, its 8th consecutive year of revenue growth. Guardant Health reported a net loss of $416.3 million, compared with a loss of $436.4 million a year earlier. Gross margin was 64.5% (up from 60.8%) and operating margin -44.5%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $982.02M | $739.02M | $563.95M | $449.54M | $373.65M |
| Growth | +32.88% | +31.04% | +25.45% | +20.31% | +30.32% |
| Net income | $-416.28M | $-436.37M | $-479.45M | $-654.59M | $-384.77M |
| EPS (diluted) | $-3.32 | $-3.56 | $-4.28 | $-6.41 | $-4.00 |
Analyst forecast
ForecastConsensus (26 analysts)
strong_buy
Avg. price target
$200.76+37.67%
- Strong buy 4
- Buy 21
- Hold 0
- Sell 0
- Strong sell 1
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 5, 2026
- EPS actual vs est.
- $-0.74 vs $-0.68
- Surprise
- -8.82%
GH news
All GH news- Guardant Health, Inc. Completes $550 Million Offering of 0% Convertible Senior Notes due 2032Nasdaq
- Guardant Health prices $500M convertible notes offeringSeeking Alpha
- Guardant Health plans $500M convertible note offering and related 2027 note repurchasesSeeking Alpha
- Guardant Health, Inc. 2026 Q3 - Results - Earnings Call PresentationSeeking Alpha
- Why is Guardant Health stock sliding today?Investing.com
- Guardant Health (GH) Q3 2026 Earnings Call TranscriptNasdaq
- What Guardant Health (GH) Said on Its Q3 Earnings CallNasdaq
- Guardant Health, Inc. (GH) Q3 2026 Earnings Call TranscriptSeeking Alpha
Guardant Health peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| DGXQuest Diagnostics Incorporated | 258.28 | -0.31% | $28.42B | vs GH |
| MOHMolina Healthcare Inc | 198.39 | -2.43% | $10.36B | vs GH |
| ILMNIllumina Inc. | 192.82 | -3.90% | $29.15B | vs GH |
| LHLabcorp Holdings Inc. | 367.13 | -0.47% | $29.81B | vs GH |
| HSICHenry Schein Inc. | 83.52 | -1.51% | $9.23B | vs GH |
| CNCCentene Corporation | 63.78 | -2.74% | $31.58B | vs GH |
| OSCROscar Health Inc. Class A | 24.73 | -5.50% | $7.68B | vs GH |
| RDNTRadNet Inc. | 69.71 | +0.29% | $5.49B | vs GH |
Indexes, lists and sector
Guardant Health stock FAQ
What is Guardant Health's stock price today?
GH last traded at $145.83 as of Nov 20, 4:00 PM EST, up 0.16% on the day. Prices are delayed at least 15 minutes.
Who is Guardant Health's CEO?
Dr. Helmy Eltoukhy Ph.D. is the chief executive officer of Guardant Health Inc., which has about 2,490 employees.
What is the GH 52-week high?
The 52-week high for GH is $191.05 and the 52-week low is $74.55. The stock is currently 23.7% below its high.